Akebia Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Akebia Therapeutics sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).
Akebia Therapeutics: 24 sponsored US clinical trials, 1 recruiting.
Akebia Therapeutics sponsors 24 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 21 completed. 7 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anemia, with 5 trials.
Top-decile sponsor footprint
Akebia Therapeutics ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
24 total, page 1 of 1
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
NCT06901505
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
NCT04707768
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
NCT04313153
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
NCT03992066
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
NCT03799627
A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
NCT03657290
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
NCT03799848
A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults
NCT03639155
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03254485
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
NCT03217591
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
NCT03140722
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
NCT02892149
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
NCT02865850
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02680574
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
NCT02648347
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
NCT02412449
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
NCT02327546
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
NCT02260193
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
NCT02062203
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01906489
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01381094
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01235936
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
NCT04707573
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 10 |
| Phase 3 | 7 |
What is open in the Akebia Therapeutics pipeline
1 recruiting of 24 indexed (4% open); 21 completed (88%).
Phase mix: 7 late (III/IV) vs 17 early (I/II) (early-phase heavy).
Top condition: Anemia (5 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Akebia Therapeutics: open-pipeline peers nationwide
Peers matched on 24 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Akebia Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 24 trials (± recruiting share)
- Acrotech Biopharma · 24 trials · 8% recruiting
- Agenus · 24 trials · 0% recruiting
- Blueprint Medicines Corporation · 24 trials · 25% recruiting
- Concert Pharmaceuticals · 24 trials · 0% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- National Institute on Drug Abuse (NIDA) · 4% recruiting · 335 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this Akebia Therapeutics page
24 registered trials is a research-attention snapshot, not an endorsement of Akebia Therapeutics or any single study.
- 1 of Akebia Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anemia is the condition Akebia Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Akebia Therapeutics pipeline card: 24 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.